MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common ...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...
Hosted on MSN3h
Leerink Partners Upgrades CVS Health (CVS)Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for CVS Health (NYSE:CVS) from Market ...
"The stock remains at a discounted level versus historical ranges," Cherny said. "The peer set may offer growth-adjusted valuation that are also appealing, but for CVS, it is closer to the end of its ...
Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...
Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...
Investment analysts at Leerink Partnrs reduced their FY2028 earnings per share estimates for shares of Inspire Medical Systems in a report released on Tuesday, February 11th. Leerink Partnrs analyst M ...
Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a research report issued ...
Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback